Extracorporeal Membrane Oxygenation (ECMO) Market Size, Share and Analysis By Type (Venovenous ECMO, Venoarterial ECMO), By Component (Pumps, Cannula), By Indications (Congenital Diaphragmatic Hernia, Birth Defects of The Heart), By End Use (Pediatric) Forecasts To 2032

The global Extracorporeal Membrane Oxygenation (ECMO) market was valued at USD 290.2 Million in 2023 and is expected to reach USD 385.9 Million by the year 2032, at a CAGR of 3.6%. Extracorporeal membrane oxygenation (ECMO) is a life support device used in the patients with failed lungs, and heart fails to pump sufficient blood to the body.

Rising the prevalence of cardiovascular and respiratory diseases across the globe is one of the major driver propelling the market growth. For instance, in U.S. over 18.2 million suffer from coronary artery disease; that contributes to annual healthcare expenditure of approximately USD 219 billion. Growing aged population and obesity worldwide are the primary cause leading to raised cases of coronary heart diseases. Furthermore, common medical conditions such as diabetes, anxiety, high blood pressure, and high cholesterol are reflected frequently among the old population which would potentially increase the risk of heart related diseases leading to increasing demand of device for arterial respiration. The market for ECMO is expected to surge with proliferating geriatric population across the globe, where, Europe and North America have the highest share of population with age of over sixty-five years and above. Additionally, emerging applications of ECMO for COVID-19 infections is also expected to provide dramatic boost to the adoption of the technology and its demand across the globe.

Increasing ECMO centers across the globe is reflects increasing adoption of the device in developed nations. As of 2023 approximately 400 hospitals in the U.S. provides ECMO, and is estimated to grow in the forecasted year. Adoption of new technologies such as coating the ECMO surface with synthetic and natural polymers that prevented the binding of platelets and leukocytes is expected to enhance the safety and efficacy of this technology. However high cost of the procedure may hinder the extracorporeal membrane oxygenation market growth in various parts of the world.

The COVID-19 Impact:

The sudden outbreak of COVID-19 has reported a significant inclination in the Extracorporeal Membrane Oxygenation (ECMO) market growth. As COVID-19 can trigger acute respiratory failure and/or acute cardiopulmonary failure, the FDA has stated the new policy for the treatment of COVID-19 patients, to allow usage of ECMO for longer durations. With the shortage of ventilators and a rising number of cases, it is only a matter of time before there is an increased need for ECMO to ensure the survival of critically ill patients. In March 2023, a Phoenix man was on the brink of death with a ventilator became the first patient to survive COVID-19 patient through extracorporeal membrane oxygenation (ECMO) therapy. As of 15^th April 2023, number of COVID-19 cases in ECMO are 230, 89, 14 and 9 in North America, Europe, Asia-Pacific and Latin America, respectively.

According to a survey, Covid-19 cases in the U.S. continues are increasing by 41% every day. Approximately 32,000-12,000 American COVID infected patients are expected to require extracorporeal machine oxygenation (ECMO). ECMO machines have successfully proven an effective treatment of COVID-19 in several countries outside of the U.S., such as China, South Korea, and Japan. In Japan, around 100 COVID-19 infected patients have received life-support treatment via ECMO machines. However, due to higher raw material costs, disrupted supply chain, and restricted transportation with higher excise duties, many economies are facing product shortage. To serve the smooth supply to the raised demand, the U.S. Food and Drug Administration (FDA) has issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus public health emergency. The FDA has included a list of all the devices that are capable of being used for ECMO therapy to be used for the treatment of COVID-19 patients. This policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19. As the global COVID cases surpassed line of 2 million cases, lifesaving technologies such as ECMO is expected to boom. Furthermore, even after the COVID-19 pandemic is curbed, the demand for such devices is expected to continue to grow at a high pace, as the new world will like to be prepared to future possibilities of epidemics.

Salient Features of the Extracorporeal Membrane Oxygenation Market

• Technological advancement is the key factor for market growth. In line with this, Fresenius a Germany based company received a 510(k) clearance for its Novalung system, an extracorporeal membrane oxygenation system that provide life support outside-the-body for more than six hours
• Several key players are engaged in developing and promoting their product line in ECMO field. For instance, Getinge group recently showcased its acute care therapy products- Cardiohelp and Cardiosave ECMO system in the EuroELSO Conference held in Barcelona in April, 2023.
• Strongest driving force includes increasing prevalence of cardiac and respiratory diseases, rising survival rates with ECMO, product launch by various market players and growth in number of ECMO centers
• Various organizations are engaged in developing new products in the extracorporeal membrane oxygenation market. For instance, chairman of department of surgery Zwischenberger and director of the Artificial Organ Laboratory Wang received FDA approval for Double Lumen Cannula
• Latin America has untapped opportunities which can be exploited by spreading awareness among public
• The complication associated with the ECMO, budget constraints, and lack of skilled personnel to carry out the therapy, are among a key challenges for the existing field players operating in ECMO market

Companies Considered and profiled in this market study

Getinge Group (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l. (Italy).

Deals Landscape:

• In February 2023, the U.S. FDA provided marketing approval for Novalung (a product of Fresenius Medical Care North America), a heart and lung support system for acute respiratory or cardiopulmonary failure treatment.
• Government and regulatory bodies in COVID 19 hit nations are experiencing a shortage in availability of ECMO and are approaching the manufacturers for the supply. For instance, in April 2023, U.S. - FDA issued a guidance for extracorporeal membrane oxygenation to help expand the availability of devices used in ECMO therapy.
• Extracorporeal Life Support Organization (ELSO) is engaged in providing various online Courses/Workshops in year 2023, aimed to raise awareness about applications and advantages of ECMO

Market-o-Nomics

• On the basis of type, venoarterial ECMO system of extracorporeal membrane oxygenation segment held a significant share of the global market in 2023. It is expected to reach 111.0 million with a CAGR 4.4% during the forecasted period
• On the basis of end use of the ECMO, pediatric end uses generated revenue of USD 130.3 million in 2023. Rising incidences of birth defects & premature birth, and increased global healthcare expenditure are the key factor to surge the extracorporeal membrane oxygenation market
• Due to increasing disposable income and increasing awareness about the respiratory diseases and adoption of new technologies the growth of the extracorporeal membrane oxygenation is booming in developing countries as well as developed countries.
• The Asia-Pacific region is estimated to be the fastest growing regional segment accounted the revenue of USD 51.2 million in 2023, and CAGR of 4.8% during the forecast period; owing it to growing incidence of target diseases and rising geriatric population in major countries of the region such as China, India and Japan, and improved regulatory framework
• North America is the chief revenue generator held 40.6% of the market revenue share in 2023

Key Coverage of the Report

• Region and country-wise assessment from the period 2023-2032. For the study, 2021-2022 has been utilized as historical data, 2023 as the base year, and 2023-2032, has been derived as forecasts
• Regional Competitors clinical pipeline analysis
• Demand and Supply GAP Analysis
• Market share analysis of the key industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 6 years of all the mentioned segments, and the regional markets
• Key Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments

Segments Covered

This report predicts revenue growth and CAGR at a global, regional & country level, and analyses the markets by studying the drivers, constraints, opportunities, threats, challenges, Investment opportunities, products, uses, trends, market shares in each of the sub-segments from 2023 to 2032. For the purpose of this study have segmented the global Extracorporeal Membrane Oxygenation (ECMO) market report based on type, component, application, end use and region:

Type Outlook (Revenue, USD Million; 2023-2032)

• Venovenous ECMO
• Venoarterial ECMO
• Arteriovenous ECMO

Component Outlook (Revenue, USD Million; 2023-2032)

• Pumps
• Cannula
• Oxygenators
• Gas Blender
• Heat Exchanger
• Pressure Monitor
• Bladder Reservoir
• Controller
• Gas Cylinder
• Others

Application Outlook (Revenue, USD Million; 2023-2032)

• COVID-19 (Coronavirus)
• Congenital Diaphragmatic Hernia (CDH)
• Birth Defects of the Heart
• Meconium Aspiration Syndrome (MAS)
• Severe Pneumonia
• Severe Air Leak Problems
• Severe High Blood Pressure in the Arteries of the Lungs (PPHN)
• Others

End Use Outlook (Revenue, USD Million; 2023-2032)

• Pediatric
• Adult

Regional Outlook (Revenue in USD Million; 2023-2032)

• North America
• U.S
• Canada
• Europe
• Germany
• France
• UK
• Rest of the Europe
• Asia Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
• Middle East & Africa
• Latin America
• Brazil